• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Mood Stabilizer Plus Antidepressant May Protect Against Mania

Mood Stabilizer Plus Antidepressant May Protect Against Mania

September 1, 2014
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Subject:
Bipolar Disorder

Short Description:

Mood Stabilizer plus Antidepressant May Protect Against Mania

Background:

Most of you would hesitate to put a patient with bipolar I on antidepressants without adding a mood stabilizer, in order to prevent a switch to mania. If this is your clinical practice, you are following the recommendations of the APA consensus guidelines for the treatment of bipolar depression. But the hard data to support the danger of switching is surprisingly weak. Clinical trials have not yielded consistent results. This is why we read with interest a recent study providing a bit more evidence that unopposed antidepressants can indeed cause manic switches—but only in bipolar I, and only over the short-term.

Researchers in Sweden used a national database to identify all patients during the period of 2005 to 2009 who had been diagnosed with bipolar disorder I and who started antidepressants. Of the 3,240 patients identified, nearly 35% were on antidepressant monotherapy while the remainder were also prescribed a mood stabilizer in addition to the antidepressant (in this study, lithium, valproate, or lamotrigine). Importantly, the researchers excluded all patients who had taken antidepressants in the previous year, to better reveal new “switching” events.

Records were reviewed for the occurrence of mania during the period after the antidepressant was started. It turns out that antidepressant monotherapy was, indeed, linked to an increased risk of mania—but only in the short term (0 to 3 months after starting the antidepressant)—the hazard ratio (HR) was 2.83, meaning that these patients were almost three times more likely to become manic than those also taking a mood stabilizer. However, 3 to 9 months after starting the medication, there was no higher prevalence of mania (HR 0.71).

When researchers focused on patients who were prescribed mood stabilizers in addition to antidepressants, there was no increased risk of mania at all, either in the 0 to 3 month period or the 3 to 9 month period. In fact, for these patients the 3 to 9 month risk of mania was actually reduced (HR 0.63).

The researchers recommend the use of mood stabilizers when antidepressants are prescribed in bipolar disorder, and also point out that more options are necessary for the management of bipolar depression. It should be noted that the present study did not evaluate whether atypical antipsychotics, commonly used in all phases of bipolar disorder, can also prevent the switch to mania (Viktorin A et al, Am J Psychiatry 2014;online ahead of print).

TCPR’s Take: The researchers recommend that clinicians add mood stabilizers to antidepressants for bipolar disorder I. This is not a huge surprise and is in line with how most of us practice. But don’t be overly seduced by these results. This was a retrospective study that relied upon diagnoses given by non-researcher clinicians, and not on standardized interviews. Furthermore, it was limited by a non-standardized definition of “mania,” and it did not evaluate patients with bipolar II disorder. The best we can say is that at least these results don’t contradict standard practice.

General Psychiatry
KEYWORDS bipolar_disorder mood_stabilizers research_updates
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2014
    SUBSCRIBE NOW
    Table Of Contents
    Step Right Up—Meaningful Use Incentives are Adding Up
    Op-Ed: Maintenance of Certification—Is it safe to opt out?
    Maintenance of Certification: What You Need to Know
    Using Transcranial Magnetic Stimulation (TMS) in Your Practice
    Mood Stabilizer Plus Antidepressant May Protect Against Mania
    CBT Moderately Effective in Improving Quality of Life for Anxiety Disorders
    Another Sleeping Pill on the Market: Merck’s Belsomra
    Should We Share Therapy Notes with Our Patients?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.